Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Briquilimab long-term extension study in chronic urticaria
2024-517830-17-00Phase 2Completed
- Sponsor
- Jasper Therapeutics, Inc.
- Start
- Feb 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of briquilimab in chronic urticaria (CU), chronic idiopathic urticaria (CIU), chronic inducible urticaria (CIndU) and 2 more, sponsored by Jasper Therapeutics, Inc. Primary endpoint: Incidence and severity of adverse events. Started Feb 2025; status: completed.
02
Drugs
briquilimab
03
Conditions
chronic urticaria (CU)chronic idiopathic urticaria (CIU)chronic inducible urticaria (CIndU)Cold urticaria (CU)symptomatic dermatographism (SD)
Beyond the preview
Go deeper on 2024-517830-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517830-17-00.